These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27943236)

  • 1. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.
    Jennings L; Nestor L; Molloy O; Hughes R; Moriarty B; Kirby B
    Br J Dermatol; 2017 Sep; 177(3):858-859. PubMed ID: 27943236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa.
    Nicolau J; Nadal A; Sanchís P; Pujol A; Masmiquel L; Nadal C
    Med Clin (Barc); 2024 Feb; 162(3):118-122. PubMed ID: 38044187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin use in hidradenitis suppurativa.
    Jennings L; Hambly R; Hughes R; Moriarty B; Kirby B
    J Dermatolog Treat; 2020 May; 31(3):261-263. PubMed ID: 30893570
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethics of diabetic drugs for weight loss in hidradenitis suppurativa patients.
    Katsetos M; Torre K; Grant-Kels JM
    J Am Acad Dermatol; 2024 Aug; 91(2):406-407. PubMed ID: 37558092
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
    Vilarrasa E; Nicolau J; de la Cueva P; Goday A; Gallardo F; Martorell A; Carrascosa JM
    Actas Dermosifiliogr; 2024 Jan; 115(1):56-65. PubMed ID: 37451337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging nonsurgical treatment options for hidradenitis suppurativa.
    Kerdel FA
    Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S57-9. PubMed ID: 25188460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two diseases one remedy? Systemic amyloidosis secondary to hidradenitis suppurativa: Treatment with infliximab.
    Özer İ; Karaçin C; Adışen E; Güz G; Ali Gürer M
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27862787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-standing hidradenitis suppurativa treated effectively with metformin.
    Arun B; Loffeld A
    Clin Exp Dermatol; 2009 Dec; 34(8):920-1. PubMed ID: 19323659
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidradenitis suppurativa in the pediatric population.
    Liy-Wong C; Pope E; Lara-Corrales I
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
    Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
    Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Treatments of Hidradenitis Suppurativa: More Options, Less Evidence.
    van der Zee HH; Gulliver WP
    Dermatol Clin; 2016 Jan; 34(1):91-6. PubMed ID: 26617362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide for weight loss in obese people.
    Thum T; Anker SD
    Lancet; 2010 Feb; 375(9714):551-2; author reply 552-3. PubMed ID: 20159285
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.
    Masson R; Shih T; Jeong C; Shi VY; Hsiao JL
    J Drugs Dermatol; 2023 Aug; 22(8):785-794. PubMed ID: 37556513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
    Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
    Scheinfeld N
    Dermatol Online J; 2013 Apr; 19(4):1. PubMed ID: 24021361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.